[1] [1] WANG Y, LI S, LI C. Clinical features, immunopathogenesis, and therapeutic strategies in vitiligo[J]. Clin Rev Allergy Immunol, 2021, 61(3): 299-323.

[2] [2] KAWALI A, MAHENDRADAS P, SANJAY S, et al. Viral kera-to-uveitis with choroidal vitiligo[J]. Ocul Immunol Inflamm, 2021, 29(7-8): 1324-1327.

[4] [4] CIESIELSKA A, MATYJEK M, KWIATKOWSKA K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling[J]. Cell Mol Life Sci, 2021, 78(4): 1233-1261.

[5] [5] OLONA A, HATELEY C, MURALIDHARAN S, et al. Sphingolipid metabolism during toll-like receptor 4(TLR4)-mediated macrophage activation[J]. Br J Pharmacol, 2021, 178(23): 4575-4587.

[9] [9] POST N F, EZEKWE N, NARAYAN V S, et al. The use of lasers in vitiligo, an overview[J]. J Eur Acad Dermatol Venereol, 2022, 36(6): 779-789.

[10] [10] MANDAL A, KUMAR M, KUMAR A, et al. TLR4 and TLR9 polymorphism: probable role in susceptibility among the population of Bihar for Indian visceral leishmaniasis[J]. Innate Immun, 2021, 27(6): 493-500.

[11] [11] SINGH A K, PRAKASH S, GARG R K, et al. Polymorphisms in vitamin D receptor, Toll-like receptor 2 and Toll-like receptor 4 genes links with Dengue susceptibility[J]. Bioinformation, 2021, 17(4): 506-513.

[12] [12] CLAVIJO-CORNEJO D, HERNNDEZ-GONZLEZ O, GU-TIERREZ M. The current role of NLRP3 inflammasome polymorphism in gout susceptibility[J]. Int J Rheum Dis, 2021, 24(10): 1257-1265.

[14] [14] ARANDA-URIBE I S, LPEZ-VZQUEZ J C, BARBOSA-COBOS R E, et al. TLR4 and TLR9 polymorphisms are not associated with either rheumatoid arthritis or systemic lupus erythematosus in Mexican patients[J]. Mol Biol Rep, 2021, 48(4): 3561-3565.

[15] [15] YANG Y, HU Y, ZHOU Y, et al. Lys694Arg polymorphism leads to blunted responses to LPS by interfering TLR4 with recruitment of MyD88[J]. Innate Immun, 2021, 27(6): 483-492.

[16] [16] YOON D S, LEE K M, CHOI Y, et al. TLR4 downregulation by the RNA-binding protein PUM1 alleviates cellular aging and osteoarthritis[J]. Cell Death Differ, 2022, 29(7): 1364-1378.

[19] [19] EZZEDINE K, PEEVA E, YAMAGUCHI Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial[J]. J Am Acad Dermatol, 2023, 88(2): 395-403.

[21] [21] DAUENDORFFER J N, SKAYEM C, PASSERON T. Male genital vitiligo[J]. Ann Dermatol Venereol, 2022, 149(2): 92-98.

[22] [22] PHAN K, PHAN S, SHUMACK S, et al. Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis[J]. J Dermatolog Treat, 2022, 33(1): 173-177.